Back to top

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral ...

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 | AGEN Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Agenus Inc. (AGEN)